NDAINJECTIONINJECTABLE
Approved
Feb 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
TECHNESCAN HDP (technetium tc 99m oxidronate) by Curium Pharma is clinical pharmacology during the 24 hours following injection, technetium tc 99m oxidronate is cleared from blood and other non-osseous tissues and accumulates in the skeleton and urine in humans. First approved in 1981.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECHNESCAN HDP is a technetium Tc 99m-based radiopharmaceutical injectable used for skeletal scintigraphy to visualize areas of altered bone metabolism and osteogenesis. The agent accumulates preferentially in actively metabolizing bone tissue, enabling detection of bone pathology including fractures, infections, and malignancy. Approximately 50% of the injected dose is retained in the skeleton at 24 hours post-injection.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling consolidation and reduced commercial staffing needs on the brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY During the 24 hours following injection, technetium Tc 99m oxidronate is cleared from blood and other non-osseous tissues and accumulates in the skeleton and urine in humans. Blood levels are about 10% of the injected dose at one hour post-injection and continue to fall to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, career opportunities are limited to operational, compliance, and maintenance roles rather than commercial expansion. Professionals joining this team should expect stability and process-focused work, not high-growth trajectory roles.
Manufacturing & Supply Chain Manager
Worked on TECHNESCAN HDP at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.